The LDE-paclitaxel oleate preparation was made according to the methods described in
previous studies (11 (link),27 (link),28 (link)). Briefly, a lipid
mixture composed by 135 mg cholesteryl oleate (Alfa Aesar, USA), 333 mg egg
phosphatidylcholine (Lipoid, Germany), 132 mg miglyol 812N (Sasol Germany GmbH,
Germany), 6 mg cholesterol (Fabrichem, USA) and 60 mg of paclitaxel oleate
(Pharmaceuticals Co., China), was added to an aqueous phase consisting of 100 mg of
polysorbate 80 (Merck, Germany) and 10 mL Tris-HCl buffer, pH 8.05. A pre-emulsion
was obtained by ultrasonic radiation until complete solubilization of the drug.
Emulsification of all lipids, drug and aqueous phase was obtained by high-pressure
homogenization using an Emulsiflex C5 homogenizer (Avestin, Canada). After
homogenization cycles, the formed emulsion was centrifuged and the nanoparticle
sterilized by passage through 0.22 μm pore polycarbonate filter (Millipore, USA) and
kept at 4°C until used.
previous studies (11 (link),27 (link),28 (link)). Briefly, a lipid
mixture composed by 135 mg cholesteryl oleate (Alfa Aesar, USA), 333 mg egg
phosphatidylcholine (Lipoid, Germany), 132 mg miglyol 812N (Sasol Germany GmbH,
Germany), 6 mg cholesterol (Fabrichem, USA) and 60 mg of paclitaxel oleate
(Pharmaceuticals Co., China), was added to an aqueous phase consisting of 100 mg of
polysorbate 80 (Merck, Germany) and 10 mL Tris-HCl buffer, pH 8.05. A pre-emulsion
was obtained by ultrasonic radiation until complete solubilization of the drug.
Emulsification of all lipids, drug and aqueous phase was obtained by high-pressure
homogenization using an Emulsiflex C5 homogenizer (Avestin, Canada). After
homogenization cycles, the formed emulsion was centrifuged and the nanoparticle
sterilized by passage through 0.22 μm pore polycarbonate filter (Millipore, USA) and
kept at 4°C until used.
Free full text: Click here
